Featured Articles

Genomic Health asserted the U.S commercial launch of  Oncotype DX AR-V7 Nucleus Detect test. The Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the…
Read More...

CE Mark approval was sought for EPD's Cardiac Mapping and Navigation System. The system helps electrophysiologists navigate the heart by generating a succinct 3D Map while imaging and…
Read More...

Atrium Health's Levine Children's Hospital proved to be a new trial site to test a new medicine for children that can regulate and stabilize their blood pressure in fatal circumstances.…
Read More...

Leading innovator in  treatments for atrial fibrillation (Afib), AtriCure and left atrial appendage management (LAAM) announced the rolling out of AtriClip FLEX•V Left Atrial Appendage…
Read More...

Alfa Scientific Designs, the US manufacturer of rapid, point-of care medical devices asserted that the FDA has extended the 510(k) clearance for  ALFA's iFOB with Driven Flow…
Read More...

Surgical guidance company, Endomag asserted that it has sought 510 (k) clearance from the US Food and Drug Administration to further extend the indication of its Magseed magnetic marker…
Read More...

Pfizer asserted that the Committee for Medicinal Products for human use of the European Medicines Agency has disapproved of expanding use of SUTENT to encompass the adjuvant treatment…
Read More...

CEL-SCI Corporation asserted that it was extending the expiration date of its Series DD and Series EE warrants to July 1, 2018. The Series DD and Series EE warrants were issued on…
Read More...

Hong Kong based investment firm, PacBridge Capital Partners has committed to invest C$12,000,000 in Contextual Genomics, leading Canadian Cancer genomics company headquartered in…
Read More...

Pfizer asserted that that the Committee for Medicinal products for Human use of the European Medicines Agency has adopted positive opinions extending marketing authorizations in the EU…
Read More...

AstraZeneca asserted that the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the…
Read More...

Merck and Viralytics claimed that the companies have ventured into a definitive agreement that enumerates Merck's acquisition of Viralytics emphasizing on oncolytic immunotherapy…
Read More...

Evidenced-based dual diagnosis treatment facility, Chiron Recovery executed a MAT program for the treatment of opioid addiction. Addiction is a chronic disease and just like other…
Read More...

Global pharmaceutical company, Glenmark Pharmaceuticals ventured into an exclusive agreement with Sam Chun Dang Pharma. Co. Ltd. (SCD) to develop, manufacture and market a portfolio of…
Read More...

GSK presented at the Center for Disease Control and Prevention Advisory Committee on Immunization Practices meeting that FLUARIX QUADRIVALENT exhibited 63.2% efficacy against moderate…
Read More...

Company dedicated to enhancing healthcare through earlier detection of cancer, Imagion Biosystems, asserted the appointment of Farideh Bischoff, PhD as the Vice President of Clinical…
Read More...

KAND567 is an orally available small molecule that blocks CX3CR1, the Fractalkine receptor. It is to be noted that Fractalkine receptor is an immunomodulating factor termed as …
Read More...

Maker of innovative, needle-free injection technology,  PharmaJet asserted venturing into a global license agreement with  Genexine, for the development and commercialization of DNA…
Read More...

The Janssen Pharmaceutical Companies of Johnson and Johnson asserted extrapolation of data that exemplified 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at…
Read More...

GenePOC asserted the launch of GenePOC GBS LB assay which is implied to be in its home market for the revogene instrument. The revogene is an automated stand-alone instrument that…
Read More...